Volume 7, Number 4, December 2006

Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study
Vivencio Barrios, Carlos Escobar, Alberto Calderón, Juan Pablo Tomás, Soledad Ruiz, Jose Luis Moya, Alicia Megías, Onofre Vegazo, Raúl Fernandez

The VIPE study was a prospective, non-comparative, open-label clinical evaluation of 97 hypertensive patients (69.1% female; 68.9+9.5 years; mean blood pressure (BP) 160+12/90+9 mmHg) with echocardiographic evidence of left ventricular hypertrophy (LVH). Patients were treated for six months with a candesartan-based regimen (8 mg/16 mg + HCTZ 12.5 mg + additional drugs to lower BP < 140/90 mmHg).
After six months, systolic/diastolic BP was decreased by 19.3+8/9.4+5 mmHg (p<0.001 for both), and left ventricular mass index (LVMI) decreased 17.01 g/m2 (95%CI: -13.2 to -20.99; p<0.001). During treatment with the candesartan-based regimen all echocardiographic parameters related to LVMI were significantly reduced and 28% achieved a target LVMI [< 134 g/m² (men) and < 110 g/m² (women)]. No significant changes were observed in ejection fraction, shortening fraction or LV diastolic function. Univariate analysis showed that both age (p=0.03) and diabetes (p=0.029) were predictive of LVH regression.
Thus, a candesartan-based regimen for six months significantly reduced echocardiographic LVH in hypertensive patients in general practice. The drug was very well tolerated and no serious adverse events were reported.

JRAAS 2006;7:236-242.

View full PDF article (open in new window)
Email this article

Right click on this DOI link and copy link to cite this article (What is a DOI link?)